| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
| Ausblick | ||||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 98.63 |
| Government Pension Fund - Global (The) | 2.81 |
| Roche Holding AG | 1.34 |
| Vanguard Total International Stock Index Fund | 1.28 |
| PRIMECAP Management Co. | 0.79 |
| CSIF (CH) Umbrella - Eq. Switzerland Total Market Index Blue | 0.76 |
| Vanguard Developed Markets Index Fund | 0.64 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2016 | 2017 | 2018 | 2019 | 2020 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 94’052 | 93’734 | 94’442 | 97’735 | 101’465 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.54 | 0.57 | 0.60 | 0.63 | 0.57 |
Bilanz (in Mio. EUR) - Aktiva
| 2016 | 2017 | 2018 | 2019 | 2020 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 28’670 | 31’572 | 32’244 | 31’254 | 32’942 |
| Summe Anlagevermögen | 46’266 | 45’401 | 46’392 | 48’329 | 51’752 |
| Summe Aktiva | 76’819 | 76’676 | 78’517 | 83’091 | 86’138 |
Bilanz (in Mio. EUR) - Passiva
| 2016 | 2017 | 2018 | 2019 | 2020 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 22’355 | 18’960 | 18’770 | 15’582 | 15’411 |
| Summe Fremdkapital | 50’417 | 47’669 | 48’151 | 47’224 | 46’365 |
| Summe Eigenkapital | 26’402 | 29’007 | 30’366 | 35’867 | 39’773 |
| Summe Passiva | 76’819 | 76’676 | 78’517 | 83’091 | 86’138 |
Adresse
| Grenzacherstrasse 124, 4070 Basel | |
| Telefon | +41 (61) 688-11-11 |
| Fax | +41 (61) 691-93-91 |
| URL | http://www.roche.com |
Management
|
Alan Hippe
Chief Financial & Information Technology Officer |
|
André S. Hoffmann
Vice Chairman |
|
Anita Hauser
Director |
|
Bernard J. Poussot
Non-Executive Director |
|
Christoph Franz
Chairman |
|
Claudia Süssmuth Dyckerhoff
Director |
|
Cristina A. Wilbur
Head-Group Human Resources |
|
Gallia Levy
Associate Group Medical Director-Hematology |
|
Gottlieb A. Keller
Secretary & General Counsel |
|
Hans Clevers
Director |
|
Jason S. Ehrlich
Senior Group Medical Director |
|
Jorg Duschmale
Director |
|
Julie Brown
Director |
|
Karl Mahler
Head-Investor Relations |
|
Karsten Jung
Global Product Strategy Head |
|
Michael D. Varney
Head-Genentech Research & Early Development |
|
Pablo Umaña
Head-Cancer Immunotherapy Discovery |
|
Patrick Frost
Director |
|
Paul Bulcke
Non-Executive Director |
|
Per-Olof Attinger
Secretary-Executive Committee & Head-CEO Office |
|
Richard P. Lifton
Non-Executive Director |
|
Severin Schwan
Chief Executive Officer & Executive Director |
|
Urs Jaisli
Chief Compliance Officer |
|
William Pao
Head-Pharma Research & Early Development |